The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | CD58 status impacts CAR T-cell activity in LBCL patients
Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, shares novel findings on the impact of CD58 status on CD19-directed chimeric antigen receptor (CAR) T-cell therapy response in large B-cell lymphoma (LBCL) patients. CD58, a CD2 ligand which provides co-stimulation to T-cells, is lost or mutated in approximately 20% of LBCL. An investigation which tested patients treated with axicabtagene ciloleucel (axi-cel) for CD58 aberrations identified CD58 status as a novel biomarker for CAR T-cell therapy response, with progression-free survival (PFS) being significantly reduced in those with aberrant CD58. Durable complete responses were rarely achieved in these individuals. CD58 knockout models found that cytolytic activity of CAR T-cells was significantly reduced compared to wildtype tumor cells. The need for CD2 signalling for CAR T-cell activation was identified and CAR T-cell administration with a CD2 receptor in trans was trialled. Substantial anti-tumor activity was seen. These findings may allow the generation of novel CAR T-cell therapies capable of overcoming CD58 loss in LBCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
